By Dhirendra Tripathi
Investing.com – Johnson & Johnson (NYSE:JNJ) stock was trading weaker in Tuesday’s premarket, after cases of adverse reaction in patients who had been administered the company’s Covid-19 jab emerged, forcing the U.S. authorities to pause the vaccination at various sites.
A joint statement issued Tuesday by the Centers for Disease Control and Prevention and the FDA said they were reviewing data of a rare and severe type of blood clot in six women days after they were vaccinated. One of the six died, while another is in hospital in a critical condition.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” the Food and Drug Administration said in a tweet.
J&J stock was down 2.6% by 8 AM ET in response.
It’s a big setback for the company and a troubling one for the country’s vaccination campaign. The fact that J&J’s vaccine only needs a single shot, rather than the two required by Pfizer ‘s (NYSE:PFE) and Moderna’s, means that it’s a faster way to immunize more people.
As of Monday, more than 6.8 million doses of the J&J vaccine had been administered in the U.S.
J&J Slips As Adverse Reactions Force FDA To Put Pause On Its Covid Jabs
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.